Jim Cramer’s renewed endorsement of Moderna signals growing confidence in its mRNA pipeline and potential stock upside
Executive summary: Jim Cramer stated he now likes having a position in Moderna for the first time in ages. His endorsement may sway investor sentiment and highlights recent positive developments in Moderna's mRNA pipeline.
Who is involved: Jim Cramer, Moderna, retail investors
Likely next: Increased retail interest could exert upward pressure on Moderna's stock, prompting further analyst commentary.
Jim Cramer, a prominent TV personality and former hedge fund manager, said he now likes having a position in Moderna for the first time in ages. This shift may reflect recent positive developments such as favorable FDA votes or pipeline updates. While no specific financial details were provided, the comment could influence retail investor sentiment toward the biotech stock.
What's next — scenarios
Retail Momentum Upside (35%)
Increased volatility and volume driven by retail inflows following high-profile media endorsements.
- Surge in social media sentiment spikes
- Increased retail brokerage account activity in biotech sectors
Pipeline Validation Base Case (45%)
Stock price stabilizes as market shifts focus from sentiment to clinical trial data quality.
- Positive Phase 2/3 data readout
- FDA fast-track designations
Sentiment Decay Downside (20%)
Initial rally fails to sustain as professional investors focus on cash burn rates and R&D spending.
- Quarterly earnings report showing higher-than-expected burn
- Negative updates on non-COVID pipeline candidates
What to watch
- FDA announcement regarding new mRNA pipeline candidates (next 60 days)
- Next quarterly earnings call focusing on cash runway (within 90 days)
- Clinical trial readout for RSV or flu vaccine candidates (next 90 days)
Timeline
- — Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” (Yahoo Finance)
- — Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? (Yahoo Finance)
Analysis — what this means
Likely next events
- Potential increase in retail trading volume for Moderna
- Further analyst commentary on Moderna
Sectors affected
- Biotechnology
- Pharmaceutical
Historical parallels
- Similar commentator endorsements preceding stock rallies (e.g., Jim Cramer on Tesla in 2020)
Key entities
Sources
- Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” — Yahoo Finance
- Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? — Yahoo Finance
Related cases
- Moderna set to join the Nasdaq-100 index, replacing Warner Bros. Discovery on October 9, 2026
- Iyuno unveils CLOE platform with persistent contextual memory to streamline modern localization workflows
- Major tech and biotech stocks enter buy zones as broader indices hold steady
- Suze Orman says a breakup saved an investor more than Moderna's 180% stock surge
- Moderna's market valuation jumps $30 billion on confidence in its cancer vaccine successes
- Moderna’s mRNA melanoma vaccine success drives 176% stock jump, validating cancer immunotherapy platform